Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

59.12 -2.07 (-3.38%)
Streaming Delayed Price Updated: 3:22 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
How Is The Market Feeling About CRISPR Therapeutics?
 
Via Benzinga
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP)
This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading the developmental race). 
Via The Motley Fool
Peering Into CRISPR Therapeutics's Recent Short Interest
 
Via Benzinga
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Cathie Wood's ARKK Is Beating Big Tech Like It's 2020 Again — But With A Twist
Cathie Wood's ARK Innovation ETF is outperforming tech market again in 2025, driven by AI breakthroughs and the return of inflows. 
Via Benzinga
Topics Artificial Intelligence ETFs
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
This biotech's innovative approach could pay rich dividends down the road. 
Via The Motley Fool
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
Ark Invest has six main ETFs with several around for more than 10 years. A look at the top 10 holdings across the six funds and what it could mean. 
Via Benzinga
Topics ETFs
Cathie Wood's Ark Dumps Block Stock Worth $4.8 Million As Bitcoin-Heavy Company Preps Q2 Results
Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday. 
Via Benzinga
Up 50% in 3 Months, Is This Stock Still a Buy?
This biotech's innovative ways might eventually pay off. 
Via The Motley Fool
The 3 Things That Matter for CRISPR Therapeutics Now
As time marches on, the factors that could make or break this stock are becoming crystal clear. 
Via The Motley Fool
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. 
Via Benzinga
Cathie Wood Doesn't Need Tesla To Win—ARKK Delivers A Blowout While EV Giant Idles
During the pandemic-fueled boom of 2020, Cathie Wood's Ark Innovation ETF (NYSE:ARKK) was one of the hottest funds on Wall Street, surging nearly 400% off its March 2020 lows. But that euphoria peaked... 
Via Benzinga
Topics ETFs
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
3 Monster Stocks to Hold for the Next 10 Years
These companies have compelling long-term futures, but the coming decade could prove particularly exciting as each one comes into its own. 
Via The Motley Fool
CRISPR Stock Surges in Recent Weeks: What's Going On?
 
Via Benzinga
10 Monster Stocks to Hold for the Next 10 Years
Each of these 10 businesses offers a market-leading product or service within an industry that's set to explode. 
Via The Motley Fool
Cathie Wood-Led Ark Launches Buffer ETFs For Its Flagship ARKK, Analyst Says It's Like Diet Soda — 50% Loss Protection, But There's A Catch
Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK),... 
Via Benzinga
Topics ETFs
2 Beaten-Down Stocks With Massive Upside Potential
Via The Motley Fool
2 Growth Stocks to Buy Hand Over Fist in July
These companies are poised to produce fireworks for your portfolio over the coming years. 
Via The Motley Fool
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy
The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in. 
Via Benzinga
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Via The Motley Fool
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.